Why Is CVS Group Down Today?

CVS Group plc shares fell 0.61% today to around 1,298.00p, as the UK veterinary services group continues to navigate the aftermath of a lengthy Competition and Markets Authority investigation into the sector, even as the CMA's final decision has now brought greater clarity.

The decline comes despite continued growth in Revenue and adjusted EBITDA, with the company's Australian expansion strategy providing an important growth offset to a softer UK consumer backdrop.

Key Highlights

CVS Group's H1 2026 interim results showed revenue from continuing operations increase 5.8% to £356.9 million, with like-for-like sales growth of 2.7% and adjusted EBITDA up 3.9% to £67.7 million, maintaining an EBITDA Margin of 19.0%, within the Group's medium-term ambition of 19% to 23%.

The CMA published its Final Decision on 24 March 2026 on its veterinary market investigation, and CVS said it already complies with many of the remedies, with price lists published on practice websites and over 80% of UK companion animal practices jointly branded, bringing welcome regulatory certainty after an extended review process.

About CVS Group PLC

CVS Group is a UK-listed veterinary group and leading provider of veterinary services, operating a network of companion animal practices across the UK alongside a growing presence in Australia, where it has been actively pursuing an acquisition-led growth strategy.

The Group recently completed its move to the Main Market of the London Stock Exchange, having previously been listed on AIM, reflecting the scale the Business has achieved as one of the UK's leading veterinary services consolidators.

Key Reasons Behind Today's Decline

Today's fall reflects continued market caution around the practical implementation of the CMA's remedies following its Final Decision, even though CVS has stated it welcomes the certainty this brings and is well advanced in complying with the various requirements, including transparency measures such as published price lists and joint branding.

Management has also flagged that the economic backdrop in the UK remains challenging, with low consumer confidence impacting footfall in companion animal practices, a headwind that continues to weigh on UK like-for-like growth even as the Group's Australian operations perform ahead of business plans.

CMA Investigation Reaches Resolution

The Competition and Markets Authority's multi-year investigation into the UK veterinary services market has moved through several stages, with a provisional decision published in October 2025 refining proposed remedies from 28 to 21, before the Final Decision was published on 24 March 2026, bringing much-needed certainty to the sector after a period of regulatory uncertainty.

CVS has consistently engaged constructively with the CMA throughout the process, implementing measures such as price list transparency and joint branding across its practices, and management has expressed confidence that it will have the opportunity to return to UK acquisitions at appropriate multiples in due course as the regulatory picture clarifies.

Australia Continues to Drive Growth

CVS Group's Australian operations have been a consistent bright spot, with practices collectively performing ahead of the Group's business plans, partly driven by buying synergies as the Group's scale in the market has grown, now operating across a substantial and expanding number of practice sites.

The Group has continued to exchange contracts on further Australian practice acquisitions, with a strong pipeline of additional opportunities, reflecting management's confidence in the country as a key growth market that can offset softer trading conditions in the UK.

Risks

The practical implementation of the CMA's remedies carries ongoing execution risk, and while CVS believes it is well advanced in compliance, any unexpected additional requirements or slower-than-expected implementation could affect the Group's operating model or cost base.

The softer UK consumer backdrop, with low consumer confidence impacting footfall in companion animal practices, represents an ongoing headwind to UK like-for-like sales growth, and any further deterioration in UK economic conditions could weigh on domestic performance.

As the Group returns to UK acquisitions following the CMA process, integration risk and the availability of accretive Acquisition opportunities at appropriate multiples will be important factors in sustaining the Group's historical growth-through-consolidation strategy.

Valuation

CVS Group's valuation reflects a business that has successfully navigated a lengthy and uncertain regulatory investigation, now benefiting from greater clarity following the CMA's Final Decision, alongside continued strong growth from its Australian operations offsetting a more challenging UK consumer backdrop.

The Group's recent move to the Main Market of the London Stock Exchange may support broader institutional investor interest over time, with the resumption of UK acquisitions at appropriate multiples representing a potential additional catalyst for growth.

What Investors Should Watch Next

Investors should monitor the practical implementation of the CMA's remedies across CVS's UK practice network, alongside continued growth momentum in the Group's Australian operations.

The pace and terms of any resumed UK acquisition activity, and broader UK consumer confidence trends affecting companion animal practice footfall, will also be important factors for the stock going forward.

Conclusion

CVS Group's 0.61% decline today reflects continued market caution around the implementation of CMA remedies following the regulator's Final Decision, even as the Group has delivered continued revenue and EBITDA growth alongside strong performance from its Australian operations.

With regulatory clarity now established and a path back to UK acquisitions in view, CVS Group's underlying growth strategy remains intact, though a challenging UK consumer backdrop and the practical costs of CMA compliance will be important factors for investors to watch.